Compare Becton Dickinson and Co (BDX) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Manhattan Associates Inc — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Manhattan Associates Inc trades at $190.49 (market cap $11.41B). The key difference: Becton Dickinson and Co is far larger — about 4.3× Manhattan Associates Inc's market cap, and Becton Dickinson and Co pays a 2.34% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals.
| BDX | MANH | |
|---|---|---|
Market Cap | $48.93B | $11.41B |
Sector | Health | Technology |
52-Week High | $185.39 | $220.19 |
52-Week Low | $138.62 | $120.88 |
Enterprise Value | $65.03B | $11.28B |
Dividend Yield | 2.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
MANH trades at $195.23, up 2.41% in the last 24 hours, with a bullish technical outlook supported by a golden cross and strong momentum indicators. The company reported Q2 2026 EPS of $1.39, beating estimates, and maintains robust profitability with an 18.67% net income margin. However, high valuation ratios like a P/E of 56.07 and ongoing legal investigations pose concerns.
Outlook is positive with an 80% analyst buy rating and a $210.33 consensus price target, implying ~8% upside. Key risks include elevated valuation multiples and fiduciary duty investigations by Rosen Law Firm, which could impact investor confidence near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
